Internal Medicine, Hematology · Columbus, OH
NPI
1033641345
Since 2017
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
460 W 10th Ave
Columbus, OH, 43210
Phone (614) 293-3196
Groups this clinician bills Medicare through
Medicare paid, 2024
$30K
411 services
Medicare patients, 2024
108
Average age 72
Drug cost, 2024
$2.7M
203 prescriptions
Company payments, 2025
$6,768
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Andrew Srisuwananukorn was code 99233 (hospital e&m - subsequent), 154 times for 43 patients. In total Andrew Srisuwananukorn billed 411 services in 10 codes, and Medicare paid $30K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 154 | 43 | $85.87 | $13K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 107 | 52 | $12.11 | $1,296 |
| 99215 Office E&M - Established | Facility | 79 | 40 | $103.75 | $8,196 |
| 99239 Hospital Discharge Management | Facility | 22 | 22 | $82.06 | $1,805 |
| 99205 Office E&M - New | Facility | 21 | 21 | $137.13 | $2,880 |
| 99223 Hospital E&M - Initial | Facility | 19 | 19 | $125.74 | $2,389 |
By year: 2023 $7,001 for 76 services; 2024 $30K for 411 services.
Medicare prescription drug claims, 2024
In 2024, the drug Andrew Srisuwananukorn prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 49 prescriptions and refills. In total Andrew Srisuwananukorn wrote 203 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 49 | 49 | Under 11 | $795K |
| Ojjaara Momelotinib Dihydrochloride | 39 | 39 | Under 11 | $1.0M |
| Hydroxyurea Generic | 24 | 34 | Under 11 | $574 |
Brand drugs: 143 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Andrew Srisuwananukorn $6,768 ($6,768 in general payments such as food, travel and fees) from 4 companies. The largest payer was Incyte Corporation with $3,488.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.